VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

Peter Black, MD
Published: Wednesday, Aug 09, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x